Revance Therapeutics Inc (RVNC) Shares Bought by Deutsche Bank AG

Deutsche Bank AG raised its stake in Revance Therapeutics Inc (NASDAQ:RVNC) by 51.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 331,820 shares of the biopharmaceutical company’s stock after acquiring an additional 112,193 shares during the quarter. Deutsche Bank AG owned approximately 0.75% of Revance Therapeutics worth $6,678,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Rothschild & Co. Asset Management US Inc. boosted its stake in Revance Therapeutics by 1.2% in the fourth quarter. Rothschild & Co. Asset Management US Inc. now owns 49,441 shares of the biopharmaceutical company’s stock valued at $995,000 after acquiring an additional 590 shares during the last quarter. State Board of Administration of Florida Retirement System boosted its stake in Revance Therapeutics by 8.5% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 11,492 shares of the biopharmaceutical company’s stock valued at $231,000 after acquiring an additional 900 shares during the last quarter. Legal & General Group Plc boosted its stake in Revance Therapeutics by 21.7% in the fourth quarter. Legal & General Group Plc now owns 6,445 shares of the biopharmaceutical company’s stock valued at $130,000 after acquiring an additional 1,150 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Revance Therapeutics by 97.2% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,352 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 1,159 shares during the last quarter. Finally, Teachers Advisors LLC boosted its stake in Revance Therapeutics by 4.6% in the third quarter. Teachers Advisors LLC now owns 62,902 shares of the biopharmaceutical company’s stock valued at $1,563,000 after acquiring an additional 2,741 shares during the last quarter. Hedge funds and other institutional investors own 79.90% of the company’s stock.

NASDAQ RVNC opened at $13.49 on Monday. Revance Therapeutics Inc has a 12-month low of $12.87 and a 12-month high of $34.20. The company has a market capitalization of $593.96 million, a PE ratio of -3.42 and a beta of 0.83.

Revance Therapeutics (NASDAQ:RVNC) last posted its quarterly earnings results on Tuesday, February 26th. The biopharmaceutical company reported ($1.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.95) by ($0.17). Revance Therapeutics had a negative net margin of 3,824.22% and a negative return on equity of 73.66%. On average, sell-side analysts expect that Revance Therapeutics Inc will post -3.54 EPS for the current year.

Several analysts have recently issued reports on the stock. Zacks Investment Research lowered shares of Revance Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, March 14th. ValuEngine raised shares of Revance Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, April 1st. Wells Fargo & Co assumed coverage on shares of Revance Therapeutics in a research report on Friday, February 15th. They issued a “market perform” rating and a $17.83 price target on the stock. HC Wainwright assumed coverage on shares of Revance Therapeutics in a research report on Thursday, February 14th. They issued a “buy” rating and a $25.00 price target on the stock. Finally, Mizuho reissued a “buy” rating on shares of Revance Therapeutics in a research report on Wednesday, February 27th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $33.26.

In related news, CEO L Daniel Browne sold 11,613 shares of the company’s stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $15.51, for a total transaction of $180,117.63. Following the sale, the chief executive officer now owns 165,687 shares of the company’s stock, valued at approximately $2,569,805.37. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 18,182 shares of company stock worth $295,218 in the last ninety days. 5.20% of the stock is currently owned by insiders.

WARNING: This piece of content was first posted by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.baseballdailydigest.com/news/2019/04/22/revance-therapeutics-inc-rvnc-shares-bought-by-deutsche-bank-ag.html.

Revance Therapeutics Profile

Revance Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which is in phase III clinical trials to treat glabellar (frown) lines and cervical dystonia; and in phase II clinical trials for the treatment of plantar fasciitis, adult upper limb spasticity, and chronic migraine.

Recommended Story: Why are gap-down stocks important?

Institutional Ownership by Quarter for Revance Therapeutics (NASDAQ:RVNC)

Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.